On September 6, 2022 GlycoMimetics, Inc. (Nasdaq: GLYC), a clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, reported that Edwin Rock, M.D., Ph.D. has joined the executive leadership team as Chief Medical Officer (CMO) (Press release, GlycoMimetics, SEP 6, 2022, View Source [SID1234619060]). Dr. Rock brings nearly two decades of biopharmaceutical clinical development experience, most recently serving as CMO for Partner Therapeutics, a privately-held commercial stage biotech based in Massachusetts.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are thrilled to have Ed join the GlycoMimetics team. His proven biopharmaceutical leadership in the development and commercialization of novel hematologic therapies will be a significant asset as we prepare for the readout of uproleselan’s pivotal Phase 3 data in relapsed/refractory AML," said Harout Semerjian, Chief Executive Officer. "With this hire we continue to build a world-class leadership team dedicated to delivering our transformation from a research company to a commercially focused organization that improves outcomes for patients."
As CMO at Partner Therapeutics, Dr. Rock led clinical development and regulatory functions for sargramostim, a U.S. Food and Drug Administration (FDA) approved therapy used in multiple therapeutic settings, including for patients with hematologic malignancies such as acute myeloid leukemia (AML). Prior to this role, as Vice President of Clinical Research at Macrogenics, Dr. Rock was clinical project leader for the first cycle approval of a successful biologics license application of margetuximab, an immune-optimized anti-HER2 antibody. He previously served in clinical development leadership roles at Astex Pharmaceuticals, Otsuka, and GSK leading clinical trial programs for drug candidates across hematology and oncology.
Dr. Rock also brings experience in the regulatory and financial fields. Early in his career, he was a Medical Officer in oncology drug review at the U.S. FDA, as well as Vice President at Leerink Swann and Company, where he performed buyside analysis of the biotechnology sector.
Dr. Rock holds a B.A. in Biology and Economics from Swarthmore College, as well as Ph.D. in Microbiology and Immunology and M.D. degrees from the Stanford University School of Medicine. He completed medical residency training at Brigham and Women’s Hospital in Boston, MA, a medical oncology fellowship at the University of Pennsylvania, and a postdoctoral fellowship in vaccine engineering at Stanford.
About Uproleselan
Discovered and developed by GlycoMimetics, uproleselan is an investigational, first-in-class, targeted inhibitor of E-selectin. Uproleselan (yoo’ pro le’sel an), currently in a comprehensive Phase 3 development program in AML, has received Breakthrough Therapy designation from the U.S. FDA and from the Chinese National Medical Products Administration for the treatment of adult AML patients with relapsed or refractory disease. Uproleselan is designed to block E-selectin (an adhesion molecule on cells in the bone marrow) from binding with blood cancer cells as a targeted approach to disrupting well-established mechanisms of leukemic cell resistance within the bone marrow microenvironment.